Minimally invasive biopsy‐based diagnostics in support of precision cancer medicine
Precision cancer medicine (PCM) to support the treatment of solid tumors requires minimally invasive diagnostics. Here, we describe the development of fine‐needle aspiration biopsy‐based (FNA) molecular cytology which will be increasingly important in diagnostics and adaptive treatment. We provide s...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-11-01
|
| Series: | Molecular Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/1878-0261.13640 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846172928315490304 |
|---|---|
| author | Bo Franzén Gert Auer Rolf Lewensohn |
| author_facet | Bo Franzén Gert Auer Rolf Lewensohn |
| author_sort | Bo Franzén |
| collection | DOAJ |
| description | Precision cancer medicine (PCM) to support the treatment of solid tumors requires minimally invasive diagnostics. Here, we describe the development of fine‐needle aspiration biopsy‐based (FNA) molecular cytology which will be increasingly important in diagnostics and adaptive treatment. We provide support for FNA‐based molecular cytology having a significant potential to replace core needle biopsy (CNB) as a patient‐friendly potent technique for tumor sampling for various tumor types. This is not only because CNB is a more traumatic procedure and may be associated with more complications compared to FNA‐based sampling, but also due to the recently developed molecular methods used with FNA. Recent studies show that image‐guided FNA in combination with ultrasensitive molecular methods also offers opportunities for characterization of the tumor microenvironment which can aid therapeutic decisions. Here we provide arguments for an increased implementation of molecular FNA‐based sampling as a patient‐friendly diagnostic method, which may, due to its repeatability, facilitate regular sampling that is needed during different treatment lines, to provide tumor information, supporting treatment decisions, shortening lead times in healthcare, and benefit healthcare economics. |
| format | Article |
| id | doaj-art-05a9329b194b4affa00fd71ebfc9b4aa |
| institution | Kabale University |
| issn | 1574-7891 1878-0261 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Molecular Oncology |
| spelling | doaj-art-05a9329b194b4affa00fd71ebfc9b4aa2024-11-08T18:26:20ZengWileyMolecular Oncology1574-78911878-02612024-11-0118112612262810.1002/1878-0261.13640Minimally invasive biopsy‐based diagnostics in support of precision cancer medicineBo Franzén0Gert Auer1Rolf Lewensohn2Department of Oncology‐Pathology Karolinska Institutet Stockholm SwedenDepartment of Oncology‐Pathology Karolinska Institutet Stockholm SwedenDepartment of Oncology‐Pathology Karolinska Institutet Stockholm SwedenPrecision cancer medicine (PCM) to support the treatment of solid tumors requires minimally invasive diagnostics. Here, we describe the development of fine‐needle aspiration biopsy‐based (FNA) molecular cytology which will be increasingly important in diagnostics and adaptive treatment. We provide support for FNA‐based molecular cytology having a significant potential to replace core needle biopsy (CNB) as a patient‐friendly potent technique for tumor sampling for various tumor types. This is not only because CNB is a more traumatic procedure and may be associated with more complications compared to FNA‐based sampling, but also due to the recently developed molecular methods used with FNA. Recent studies show that image‐guided FNA in combination with ultrasensitive molecular methods also offers opportunities for characterization of the tumor microenvironment which can aid therapeutic decisions. Here we provide arguments for an increased implementation of molecular FNA‐based sampling as a patient‐friendly diagnostic method, which may, due to its repeatability, facilitate regular sampling that is needed during different treatment lines, to provide tumor information, supporting treatment decisions, shortening lead times in healthcare, and benefit healthcare economics.https://doi.org/10.1002/1878-0261.13640biomarkersfine‐needle aspiratesimmune signalingminimally invasive diagnosticssolid tumorstumor microenvironment |
| spellingShingle | Bo Franzén Gert Auer Rolf Lewensohn Minimally invasive biopsy‐based diagnostics in support of precision cancer medicine Molecular Oncology biomarkers fine‐needle aspirates immune signaling minimally invasive diagnostics solid tumors tumor microenvironment |
| title | Minimally invasive biopsy‐based diagnostics in support of precision cancer medicine |
| title_full | Minimally invasive biopsy‐based diagnostics in support of precision cancer medicine |
| title_fullStr | Minimally invasive biopsy‐based diagnostics in support of precision cancer medicine |
| title_full_unstemmed | Minimally invasive biopsy‐based diagnostics in support of precision cancer medicine |
| title_short | Minimally invasive biopsy‐based diagnostics in support of precision cancer medicine |
| title_sort | minimally invasive biopsy based diagnostics in support of precision cancer medicine |
| topic | biomarkers fine‐needle aspirates immune signaling minimally invasive diagnostics solid tumors tumor microenvironment |
| url | https://doi.org/10.1002/1878-0261.13640 |
| work_keys_str_mv | AT bofranzen minimallyinvasivebiopsybaseddiagnosticsinsupportofprecisioncancermedicine AT gertauer minimallyinvasivebiopsybaseddiagnosticsinsupportofprecisioncancermedicine AT rolflewensohn minimallyinvasivebiopsybaseddiagnosticsinsupportofprecisioncancermedicine |